There New Zealand he took a significant step in the field of psychiatry, approving the medical use of the psilocubesactive ingredient of the so -called hallucinogenic mushrooms. It is an important decision, but Very limited: the treatment can only be administered by one Highly qualified psychiatristProfessor Cameron Laceyand only in cases of resistant depression to other drugs.
Although one remains illegal substance For the general population, psilocibina has increasingly attracted the interest of the scientific community. Studies published in authoritative magazines have shown how this compound can Promote brain neuroplasticityhelping to unlock pathological psychological mechanisms.
The psychedelic effect, if controlled and led by professionalscould prove to be a powerful therapeutic tool, especially for patients with Post-traumatic stress disorder (PTSD) And serious depressions.
Australia in 2023 introduced a legislation
Deputy Prime Minister and Minister of Health David Seymour stressed that it is a Experimental and highly regulated approach. Lacey, who has already conducted clinical studies on the therapeutic use of the psychedelics, will be the only one for now authorized to prescription. The hope of the government is that other professionals can also be in the future obtain authorizationas long as they respect rigorous standards.
New Zealand follows the example of other pioneer countries such as Australiawhich in 2023 introduced a legislation, and some jurisdictions of Canada And United States. Globally, however, the situation remains fragmented: in Europefor example, the debate is still strongly conditioned by the mentality of the “war on drugs“, Which struggles to accept the idea of a therapeutic use of psychedelic substances.
In this context the initiative is inserted Psychedelicarea campaign that aims to collect one million signatures For Ask the European Union to regulate the therapies assisted by Psychedelici. The goal is to promote a more scientific and pragmatic approach, recognizing the therapeutic potential of substances so far stigmatized.
The opening of New Zealand therefore represents a courageous and far -sighted choice, which could inspire other countries To abandon old prejudices and evaluate these therapies based on data, not taboos.
